Dated: August 7, 2026.

Richard U. Rodriguez,

Associate Director, Technology Transfer Center, National Cancer Institute.

[FR Doc. 2026–16439 Filed 8–11–26; 8:45 am]

BILLING CODE 4167–05–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Health Promotion and Implementation.

Date: August 28, 2026.

Time: 9:00 a.m. to 3:30 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Andrea B. Kelly, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 451–6339, *kellya2@mail.nih.gov.*

Name of Committee: Center for Scientific Review, Special Emphasis Panel; Fellowships: Synthetic and Medicinal Chemistry and Chemical Biology deferral panel.

Date: August 31, 2026.

Time: 2:00 p.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: John J. Laffan, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 443–7154, *laffanjo@mail.nih.gov.*

Name of Committee: Risk, Prevention and Health Behavior Integrated Review Group; Biobehavioral Medicine and Health Outcomes Study Section.

Date: September 14–15, 2026.

Time: 9:30 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Mark A. Vosvick, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3110, Bethesda, MD 20892, (301) 402–4128, *mark.vosvick@nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: August 7, 2026.

Margaret N. Vardanian,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2026–16377 Filed 8–11–26; 8:45 am]

BILLING CODE 4167–05–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in-class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (*e.g.,* COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.

FOR FURTHER INFORMATION CONTACT: Inquiries related to this license/co-development opportunity should be directed to: Aida Cremesti, Ph.D., Senior Technology Transfer Manager, NCI, Technology Transfer Center, Email: *aida.cremesti@nih.gov* or Phone: 240–276–6641.

SUPPLEMENTARY INFORMATION: Investigators at the National Cancer Institute (NCI) have identified and therapeutically validated a distinctive, disease-restricted driver of thrombosis: soluble tissue factor (sTF). sTF is generated through proteolytic cleavage during inflammatory cell death. Mechanistically, the researchers demonstrated that sTF generation is not limited to necroptosis but represents a conserved outcome of multiple inflammatory cell death pathways, including pyroptosis and NETtosis.

Pathological thrombosis remains a leading cause of morbidity and mortality in sepsis, cancer, autoimmune diseases, viral infections, and inflammatory disorders. Current anticoagulant and thrombosis treatments options such as Heparins and Warfarin are effective at reducing clot formation, but act indiscriminately on the coagulation cascade, disrupt normal hemostasis, and are associated with significant bleeding risk. Current thrombosis diagnostics, D-dimer, a fibrin degradation by product, is a late stage markers that lacks sensitivity. This invention provides an alternative for early detection based on sTF that is more sensitive and specific.

To selectively target this mechanism, the team developed novel humanized monoclonal antibodies (*e.g.,* 58B3 and 56E5) that specifically recognize human soluble tissue factor (hsTF), but not full-length membrane-bound tissue factor (flTF). This selectivity preserves physiological hemostasis while inhibiting pathological coagulation. *In vivo* validation using human samples of various clinical diseases demonstrated that administration of sTF-specific antibodies prevents fibrinogen depletion and reduces thrombin–antithrombin (TAT) complex elevation, effectively normalizing coagulation parameters. These results establish proof of concept that selective sTF neutralization can block pathological thrombosis without systemic anticoagulation.

By establishing sTF as a unifying mechanistic link between inflammatory cell death and thrombosis across sepsis, cancer, infection, autoimmune disease, cardiovascular disorders, and metabolic inflammation, this antibody platform represents a first-in-class strategy to selectively inhibit pathological

coagulation while preserving normal hemostasis. The approach offers a safer, more precise therapeutic and diagnostic alternative to conventional anticoagulants. The humanized monoclonal antibodies, as well as methods of using sTF as a target for diagnosis, treatment and prevention of thrombosis and associated diseases are available for licensing or collaborative development to advance clinical translation. Partnership opportunities include preclinical optimization, clinical development, and diagnostic assay co-development.

''This Notice is in accordance with 37 CFR 404.4 Authority to grant licenses.''

NIH Reference Number: E–263–2023.

Related Technologies: N/A.

Product Type: Therapeutic.

Therapeutic Area(s): Cardiology | Infectious Diseases | Oncology.

Development Stage: Pre-clinical (*in vivo* validation).

Publications:

- Wan, P., Choksi, S., Park, YJ. *et al.* Soluble tissue factor generated by necroptosis-triggered shedding is responsible for thrombosis. *Cell Res* 35, 840–858 (2025). *https://doi.org/10.1038/s41422-025-01167-8.*
- Yan J, Wan P, Choksi S, Liu ZG. Necroptosis and tumor progression. *Trends Cancer,* 2022 Jan;8(1):21–27. *https://doi.org/10.1016/j.trecan.2021.09.003.*

Patents: PCT/US2026/022285, filed April 3,2026.

Potential Commercial Applications:

- Diagnostic tool for early detection and monitoring of sTF in plasma.
- Diagnostic tool for early detection and monitoring of thrombosis, much more sensitive and specific test than the currently used D-dimer test.
- Basis for diagnostic kits such as ELISA and point-of-care assays.
- Diagnostic tool for early detection of DVT and PE with radiolabeled anti-sTF antibody in combination with ultrasound/CT scan.
- Therapeutic use for sepsis-associated thrombosis.
- Therapeutic use for cancer-associated thrombosis.
- Therapeutic use viral infection–associated thrombosis.
- Therapeutic use autoimmune disorders.
- Therapeutic use cardiovascular inflammatory diseases.
- Therapeutic use for acute lung injury including Acute Respiratory Distress Syndrome ARD.
- Therapeutic use for metabolic and vascular inflammatory diseases.
- Therapeutic use for highly efficient inhibition of thrombosis with anti-sTF-based bispecific antibodies.

Competitive Advantages:

- Selective targeting of pathological soluble tissue factor (sTF).
- Preservation of normal hemostasis.
- Potential for long-acting biologic prevention.
- Specific mechanism-based intervention tied to inflammatory cell death.

Collaboration Opportunity: Researchers at the NCI seek licensing and/or co-development for developing diagnostic, prognostic, preventative and therapeutic development of sTF. NCI is seeking collaborators with access to clinical samples of thrombosis, and with experience of *in vivo* detection of thrombosis (*e.g.,* DVT) in patients with current tools. Also seeking collaborators with experience in developing bi-specific antibodies.

Dated: August 7, 2026.

Richard U. Rodriguez,

Associate Director, Technology Transfer Center, National Cancer Institute.

[FR Doc. 2026–16440 Filed 8–11–26; 8:45 am]

BILLING CODE 4167–05–P

DEPARTMENT OF THE INTERIOR

Fish and Wildlife Service

[Docket No. FWS–R7–ES–2026–2312; FXES111607MRG01–267–FF07CAMM00]

Marine Mammals; Incidental Take During Specified Activities; Proposed Incidental Harassment Authorization for Southeast Alaska Stock of Northern Sea Otters in Juneau, Alaska

AGENCY: Fish and Wildlife Service, Interior.

ACTION: Notice of receipt of application; proposed incidental harassment authorization; draft environmental assessment; request for comments.

SUMMARY: We, the U.S. Fish and Wildlife Service (FWS), propose to authorize incidental take by harassment of small numbers of northern sea otters (*Enhydra lutris kenyoni*) from the Southeast Alaska stock for a period of up to 1 year from the date of issuance. We are responding to a request submitted under the Marine Mammal Protection Act of 1972, as amended, by Turnagain Marine Construction. The applicant has requested this authorization for take by harassment that may result from activities associated with pile driving and marine construction within Stephens Passage in Juneau, Alaska. This proposed authorization, if finalized, would be for incidental take by Level A harassment and Level B harassment of northern sea otters from the Southeast Alaska stock. We invite comments on the proposed incidental harassment authorization and the accompanying draft environmental assessment from the public, Tribes, and local, State, and Federal agencies.

DATES: Comments must be received by September 11, 2026.

ADDRESSES: *Document availability:* You may view the application package, the draft environmental assessment, and other supporting material at *https://www.regulations.gov* under Docket No. FWS–R7–ES–2026–2312, or you may request these documents from the person listed under **FOR FURTHER INFORMATION CONTACT**.

- *Comment submission:* All submissions must include the docket number [FWS–R7–ES–2026–2312] for this document. You must submit comments using one of the following methods:
- *Electronic submission:* Go to the Federal eRulemaking Portal: *https://www.regulations.gov.* In the Search box, enter FWS–R7–ES–2026–2312, which is the docket number for this rulemaking action. Then, click on the ''Search'' button. On the resulting page, in the panel on the left side of the screen under the ''Document Type'' heading, check the Notice box to locate this document. You may submit a comment by clicking on ''Comment.'' Comments must be submitted to *https://www.regulations.gov* before 11:59 p.m. eastern time on the date specified in **DATES**.
- *U.S. mail:* Public Comments Processing, Attn: Docket No. FWS–R7–ES–2026–2312, U.S. Fish and Wildlife Service, MS: PRB (JAO/3W), 5275 Leesburg Pike, Falls Church, VA 22041–3803.

Comments submitted through any method not authorized in this document, or sent to an address not listed here, will not be considered. We will not accept comments via email, fax, or hand delivery. We are not required to consider comments that are submitted after the comment period ends or that are submitted via a method outside of these instructions. Comments containing profanity, vulgarity, threats, or other inappropriate content will not be considered.

We request that you send comments only by the methods described above. We will post all comments at *https://www.regulations.gov.* You may request that we withhold personal identifying information from public review; however, we cannot guarantee that we will be able to do so. See Request for Public Comments for more information.